Target and Its Patented Drug(s)
| Target General Information | Top | ||||
|---|---|---|---|---|---|
| Target ID | T10822 | Target Info | |||
| Target Name | Cyclin-dependent kinase 8 (CDK8) | ||||
| Synonyms | Protein kinase K35; Mediator of RNA polymerase II transcription subunit CDK8; Mediator complex subunit CDK8; Cell division protein kinase 8 | ||||
| Target Type | Clinical trial Target | ||||
| Gene Name | CDK8 | ||||
| Biochemical Class | Kinase | ||||
| UniProt ID | |||||
| Patent(s) and the Corresponding Patented Drug(s) | Top | ||||
|---|---|---|---|---|---|
| World Intellectual Property Organization (WIPO) | |||||
| Patent ID | WO2014072435 | ||||
| Title | Substituted Tricyclic Benzimidazoles As Kinase Inhibitors. | ||||
| Abstract | Disclosed are substituted tricyclic benzimidazoles compounds as defined herein in formula (I) or pharmaceutically acceptable salts thereof. The compounds of the invention selectively inhibit CDK8 and are therefore useful for treating diseases related to this kinase, especially colorectal and melanoma cancers and other solid and hemathological malignancies, autoimmune diseases and inflammatory diseases. Also disclosed are processes for preparing these compounds. | ||||
| Applicant(s) | Selvita Sa | ||||
| Representative Drug(s) | D0NY7M | Drug Info | Complete inhibition = 1000 nM | [1] | |
| Patent ID | WO2013001310 | ||||
| Title | Macrocyclic Compounds and Their Use As Cdk8 Inhibitors. | ||||
| Abstract | There is provided compounds of formula I, wherein R1, R2, R3, R4, X, Y, Z and ring A have meanings given in the description, and pharmaceutically-acceptable esters, amides, solvates or salts thereof, which compounds are useful in the treatment of diseases in which inhibition of a protein or lipid kinase (e.g. CDK8) is desired and/or required, and particularly in the treatment of cancer or a proliferative disease. | ||||
| Applicant(s) | Ct Nac Investigaciones Oncologicas Cnio | ||||
| Representative Drug(s) | D03OIA | Drug Info | IC50 = 24 nM | [1] | |
| References | Top | ||||
|---|---|---|---|---|---|
| REF 1 | Cyclin-dependent kinase inhibitors for cancer therapy: a patent review (2009 - 2014).Expert Opin Ther Pat. 2015;25(9):953-70. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.